Standardization and performance evaluation of "modified" and "ultrasensitive" versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia

Journal of Clinical Virology

Volumn 52, Issue 1, 2011, Pages 17-22

  Amendola, Alessandra ^a   Bloisi, Maria ^a   Marsella, Patrizia ^a   Sabatini, Rosella ^a   Bibbò, Angela ^a   Angeletti, Claudio ^a   Capobianchi, Maria Rosaria ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

HIV 1; Low level viremia; Minimal residual viremia; Real time PCR

Indexed keywords

VIRUS RNA;

ANALYTICAL EQUIPMENT; ARTICLE; BIOASSAY; CALIBRATION; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LIMIT OF DETECTION; MINIMAL RESIDUAL VIREMIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REALTIME HUMAN IMMUNODEFICIENCY VIRUS 1 ASSAY; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; VIREMIA; VIRUS DETECTION;

CALIBRATION; CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC TESTS, ROUTINE; HIV INFECTIONS; HIV-1; HUMANS; LIMIT OF DETECTION; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIREMIA;

EID: 79961128343     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.04.012     Document Type: Article

References (35)

1. Wong J.K., Hezareh M., Günthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
2. Dornadula G., Zhang H., VanUitert B., Stern J., Livornese L., Ingerman M.J., et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999, 282:1627-1632.
3. Natarajan V., Bosche M., Metcalf J.A., Ward D.J., Lane H.C., Kovacs J.A. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 1999, 353:119-120.
4. Palmer S., Maldarelli F., Wiegand A., et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. PNAS 2008, 105(10):3879-3884.
5. Hatano H., Delwart E.L., Norris P.J., Lee T.H., Neilands T.B., Kelley C.F., et al. Evidence of persistent low-level of viremia in long term HAART-suppressed HIV-infected patients. AIDS 2010, 24(16):2535-2539.
6. Palmer S., Wiegand A.P., Maldarelli F., Bazmi H., Mican J.M., Polis M., et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003, 41(10):4531-4536.
7. Maldarelli F., Palmer S., King M.S., Wiegand A., Polis M.A., Mican J., et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathogen 2007, 3(4):e46.
8. Pomerantz R.J. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials 2003, 4(2):137-143.
9. Tobin N.H., Learn G.H., Holte S.E., Wang Y., Melvin A.J., McKernan J.L., et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005, 79(15):9625-9634.
10. Shen L., Siliciano R.F., Viral reservoirs residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008, 122(1):22-28.
11. Sahu G.K., Paar D., Frost S.D., Smith M.M., Weaver S., Cloyd M.W. Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol 2009, 81(1):9-15.
12. McMahon D., Jones J., Wiegand A., Gange S.J., Kearney M., Palmer S., et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010, 50(6):912-919.
13. Alexaki A., Liu Y., Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008, 6(5):388-400.
14. Crowe S.M. Macrophages and residual HIV infection. Curr Opin HIV AIDS 2006, 1(2):129-133.
15. Drosten C., Panning M., Drexler J.F., Hänsel F., Pedroso C., Yeats J., et al. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain. Clin Chem 2006, 52(7):1258-1266.
16. Edelmann A., Kalus U., Oltmann A., Stein A., Unbehaun A., Drosten C., et al. Improvement of an ultrasensitive human immunodeficiency virus type 1 real-time reverse transcriptase-polymerase chain reaction targeting the long terminal repeat region. Transfusion 2010, 50(3):685-692.
17. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55(4):611-622.
18. Havlir D.V., Strain M.C., Clerici M., Ignacio C., Trabattoni D., Ferrante P., et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003, 77(20):11212-11219.
19. Nettles R.E., Kieffer T.L., Simmons R.P., Cofrancesco J., Moore R.D., Gallant J.E., et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 2004, 39(7):1030-1037.
20. Palmisano L., Giuliano M., Nicastri E., Pirillo M.F., Andreotti M., Galluzzo C.M., et al. Residual viremia in subjects with chronic HIV infection and viral load <50copies/ml: the impact of highly active antiretroviral therapy. AIDS 2005, 19(16):1843-1847.
21. Bailey J.R., Sedaghat A.R., Kieffer T., Brennan T., Lee P.K., Wind-Rotolo M., et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006, 80(13):6441-6457.
22. Shiu C., Cunningham C.K., Greenough T., Muresan P., Sanchez-Merino V., Carey V., et al. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J Virol 2009, 83(19):9731-9742.
23. Dinoso J.B., Kim S.Y., Wiegand A.M., Palmer S.E., Gange S.J., Cranmer L., et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009, 106(23):9403-9408.
24. Archin N.M., Cheema M., Parker D., Wiegand A., Bosch R.J., Coffin J.M., et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 2010, 5(2):e9390.
25. Bonora S., Nicastri E., Calcagno A., Gonzalez de Requena D., D'Ettorre G., Sarmati L., et al. Ultrasensitive assessment of residual HIV viremia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 2009, 81(3):400-405.
26. Nicastri E., Palmisano L., Sarmati L., D'Ettorre G., Parisi S., Andreotti M., et al. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNAcp/ml) during different antiretroviral regimens. Curr HIV Res 2008, 6(3):261-266.
27. Garrido C., Geretti A.M., Zahonero N., Booth C., Strang A., Soriano V., et al. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010, 65(2):320-326.
28. Gandhi R.T., Zheng L., Bosch R.J., Chan E.S., Margolis D.M., Read S., et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010, 7(8).
29. Raboud J.M., Montaner J.S.G., Conway B., et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long term response to therapy. AIDS 1998, 12:1619-1624.
30. Powderly W.G., Saag M.S., Chapman S., et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999, 13:1873-1880.
31. Langford S., Gayet-Ageron A., Duncombe C., Jupimai T., Mahanontharit A., Kiertiburanakul S., et al. Supersensitive Viral load assay in predicting CD4-guided treatment failure. Open Virol J 2008, 2:69-73.
32. Picado J.C., Morales-Lopetegi K., Wrin T., et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002, 16:895-899.
33. Sahu G.K., Sarria J.C., Cloyd M.W. Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy. J Virol 2010, 84(16):8348-8352.
34. Havlir D.V., Bassett R., Levitan D., Gilbert P., Tebas P., Collier A.C., et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001, 286(2):171-179.
35. Piwowar-Manning E.M., Henderson T.A., Brisbin L., Jackson J.B. A modified ultrasensitive assay to detect quantified HIV-1 RNA of fewer than 50 copies per milliliter. Am J Clin Pathol 2003, 120(2):268-270.